VPR-254: an inhibitor of ROR-gamma T with potential utility for the treatment of inflammatory bowel disease.


Journal

Inflammopharmacology
ISSN: 1568-5608
Titre abrégé: Inflammopharmacology
Pays: Switzerland
ID NLM: 9112626

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 23 05 2019
accepted: 09 09 2019
pubmed: 25 9 2019
medline: 5 1 2021
entrez: 25 9 2019
Statut: ppublish

Résumé

Retinoic Acid Related Orphan Nuclear Receptor gamma T (RORγT) is a lineage specifying transcription factor for IL-17 expressing cells, which may contribute to the pathogenesis of Inflammatory Bowel Disease (IBD). VPR-254 is a selective in vitro inhibitor of RORγT. The main goals of our study were twofold: (1) To determine if ex vivo treatment with VPR-254 reduced relevant cytokine (IL-17 and IL-21) secretion from colonic strips of mice with colitis; (2) To determine if treatment of mice with VPR-254 attenuated parameters of colitis, using three murine IBD models. VPR-254 was evaluated ex vivo in a colonic strip assay, using tissue from mice with Dextran sulfate sodium (DSS)-induced colitis. In vivo, VPR-254 was evaluated for efficacy in DSS, Trintirobenzenesulfonic acid (TNBS) and Anti-CD40 antibody-induced murine models of colitis. VPR-254 reduced the production of key pro-inflammatory cytokines (e.g., IL-17) in ex vivo and in vivo models of colitis. This small molecule inhibitor of RORγT also improved various morphometric and histological parameters associated with three diverse murine models of IBD. Our results support the concept that an inhibitor of ROR-gamma T may have potential utility for the treatment of IBD.

Identifiants

pubmed: 31549280
doi: 10.1007/s10787-019-00643-z
pii: 10.1007/s10787-019-00643-z
doi:

Substances chimiques

Cytokines 0
Interleukin-17 0
Nuclear Receptor Subfamily 1, Group F, Member 3 0
Dextran Sulfate 9042-14-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

499-511

Subventions

Organisme : NIDDK NIH HHS
ID : 1R43 DK099896
Pays : United States
Organisme : NIDDK NIH HHS
ID : 2R44 DK098896
Pays : United States
Organisme : NIDDK NIH HHS
ID : 1R43 DK099896
Pays : United States
Organisme : NIDDK NIH HHS
ID : 2R44 DK098896
Pays : United States

Références

Inflamm Bowel Dis. 2006 May;12(5):382-8
pubmed: 16670527
J Leukoc Biol. 2015 Mar;97(3):499-510
pubmed: 25548251
Elife. 2016 Jan 18;5:e10066
pubmed: 26780670
Nat Med. 2016 Mar;22(3):319-23
pubmed: 26878233
Nat Rev Gastroenterol Hepatol. 2015 May;12(5):271-83
pubmed: 25971811
Mol Med Rep. 2012 Dec;6(6):1255-60
pubmed: 23008075
Int J Inflam. 2012;2012:389404
pubmed: 22506136
Gastroenterology. 2008 Apr;134(4):1038-48
pubmed: 18395085
J Exp Med. 2011 Jan 17;208(1):125-34
pubmed: 21173107
Front Immunol. 2018 Oct 22;9:2307
pubmed: 30405600
Biochem Pharmacol. 2018 Apr;150:35-45
pubmed: 29369782
Nature. 2010 Apr 29;464(7293):1371-5
pubmed: 20393462
J Immunol. 2019 Jan 1;202(1):79-92
pubmed: 30478092
Genome Biol. 2016 Mar 30;17:58
pubmed: 27029486
Inflammopharmacology. 2014 Dec;22(6):341-9
pubmed: 24715223
Aliment Pharmacol Ther. 2016 Jan;43(1):30-51
pubmed: 26515897
Immunity. 2006 Aug;25(2):309-18
pubmed: 16919486
Inflamm Bowel Dis. 2010 Oct;16(10):1763-77
pubmed: 20310011
World J Gastroenterol. 2013 Aug 7;19(29):4702-17
pubmed: 23922467
Eur J Immunol. 2012 Sep;42(9):2232-7
pubmed: 22949321
Cell Death Dis. 2019 Apr 8;10(4):315
pubmed: 30962426
Gastroenterology. 2009 Jan;136(1):257-67
pubmed: 18992745
Mucosal Immunol. 2014 Jan;7(1):143-54
pubmed: 23715173
Gut. 2009 Sep;58(9):1207-17
pubmed: 18483078
J Exp Med. 2019 Jan 7;216(1):133-151
pubmed: 30518599
Curr Pharm Des. 2012;18(9):1292-310
pubmed: 22316157
Immunity. 2008 Jan;28(1):29-39
pubmed: 18164222
Dig Dis Sci. 2012 Jul;57(7):1822-31
pubmed: 22466098
Br J Nutr. 2008 Sep;100(3):530-41
pubmed: 18279557
Inflamm Res. 2019 Jun;68(6):493-509
pubmed: 30972425
Eur J Immunol. 2015 Jun;45(6):1667-79
pubmed: 25820779
Acta Pharmacol Sin. 2015 Jan;36(1):71-87
pubmed: 25500868
Mucosal Immunol. 2012 May;5(3):240-7
pubmed: 22354322
J Exp Med. 2011 Jun 6;208(6):1127-33
pubmed: 21576383
Bioorg Med Chem Lett. 2009 Oct 1;19(19):5560-4
pubmed: 19720530
J Med Chem. 2018 Dec 27;61(24):10976-10995
pubmed: 30010338
J Pharmacol Exp Ther. 2012 Sep;342(3):850-60
pubmed: 22691298
Cytokine. 2013 May;62(2):262-71
pubmed: 23557800

Auteurs

Leo R Fitzpatrick (LR)

Department of Pharmaceutical and Biomedical Sciences Department, California Northstate University College of Pharmacy, 9700 West Taron Drive, Elk Grove, CA, 95757, USA. lfitzpatrick@cnsu.edu.
Department of Pharmacology, Penn State College of Medicine, Hershey, PA, 17033, USA. lfitzpatrick@cnsu.edu.

Jeff Small (J)

Department of Pharmacology, Penn State College of Medicine, Hershey, PA, 17033, USA.

Robert O'Connell (R)

Bolder Biopath Incorporated, Boulder, CO, 80301, USA.

George Talbott (G)

Department of Pharmaceutical and Biomedical Sciences Department, California Northstate University College of Pharmacy, 9700 West Taron Drive, Elk Grove, CA, 95757, USA.

Gordon Alton (G)

Visionary Pharmaceuticals Incorporated, San Diego, CA, 92121, USA.

Jim Zapf (J)

Visionary Pharmaceuticals Incorporated, San Diego, CA, 92121, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH